This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by pertuzumab/trastuzumab was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer during dual HER2 blockade. Here, ERBB2 is linked to breast cancer.